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A B S T R A C T
In this meta-analysis of randomized controlled trials (RCTs), the eﬀects of vitamin D supplementation on the
scores for the expanded disability status scale (EDSS) in people with multiple sclerosis (MS) are assessed. The
following databases were search up to January 2018: MEDLINE, EMBASE, Web of Science, and Cochrane Central
Register of Controlled Trials. The quality of the relevant extracted data was assessed according to the Cochrane
risk of bias tool. Data were pooled by the use of the inverse variance method and expressed as mean diﬀerence
with 95% Conﬁdence Intervals (95% CI). Six studies were included in this meta-analysis. The ﬁndings de-
monstrated that supplementation with vitamin D alone and vitamin D plus calcium did not aﬀect the EDSS score
(WMD -0.11 (-0.33, 0.11); P=0.32). In addition, subgroup analysis showed that vitamin D supplementation
alone, when compared to the use of a placebo, and vitamin D plus calcium supplementation compared with the
control did not aﬀect EDSS (WMD -0.13 (-0.30, 0.11); P= 0.29) and (WMD -0.08 (-0.57, 0.41); P=0.29),
respectively. Overall, this meta-analysis indicated that taking vitamin D in people with MS had no signiﬁcant
eﬀect on EDSS.
1. Introduction
Multiple sclerosis (MS) is deﬁned as an immune-mediated in-
ﬂammation and demyelinating disease of the central nervous system
(CNS) and is a major contributor to disability of young people [1,2]. MS
is one of the commonest causes of non-traumatic disability in young
adults in Western countries [3]. Some observational studies on en-
vironmental associations have reported that elevated exposure to sun-
light [4], reducing latitude [5], summer outdoor activities and high-
dose intake of vitamin D-rich ﬁsh oils [6] are each correlated with a
decreased risk of progressing MS.
Several observational studies have suggested that circulating levels
of vitamin D are a sign of more active disease in subjects with relapsing-
remitting multiple sclerosis (RR-MS) [7,8]. In addition, prospective and
meta-analyses studies have reported that low circulating levels of vi-
tamin D elevated the risk of mental health disturbances, such as de-
mentia [9], cognitive impairment [10], impaired motor functions [11],
and memory decline [12]. Two previous systematic reviews evaluated
the relation between vitamin D status and cognitive performance
[13,14], but there was insuﬃcient evidence to draw a conclusion. It has
been suggested that vitamin D intake in people with MS may inﬂuence
the regulation of clinical disease activity as well as inﬂuencing the
progress of disease. In a meta-analysis conducted by James et al. [15],
no detectable relationship between vitamin D supplementation and risk
of MS relapses was seen. However, the sample size of these trials was
small, the quality of diﬀerent studies was variable, the number of the
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studies was small, and the results were inconsistent.
Despite multiple randomized controlled trials (RCTs), we are aware
of no meta-analysis of RCTs on the eﬀect of vitamin D administration on
EDSS in people with MS. This current meta-analysis was conducted to
summarize the available evidence of RCTs to determine the impact of
vitamin D administration on EDSS in people with MS.
2. Materials and methods
2.1. Search strategy
Eligible RCTs were identiﬁed using Cochrane Library, Embase,
Medline, and Web of Science databases for relevant articles published
until 2018, and by manually searching the reference list of the retrieved
articles. Databases of International Standard Randomized Controlled
Trial Number Register and Meta-register for RCTs were also searched
for all ongoing trials. Studies retrieved that evaluated the impacts of
vitamin D supplementation on parameters of inﬂammation and oxida-
tive damage by using the following MeSH and text words: patients
["MS"], intervention [("vitamin D3 and/or D2″ OR "vitamin D supple-
ment" OR "vitamin D treatment" AND "supplementation" OR "intake")
OR "calcium supplement"], and outcome ["expanded disability status
scale (EDSS)"]. Additional manual searches including reference lists of
related studies; former review studies were reviewed to increase sen-
sitivity in search strategy. Studies included to this meta-analysis had the
following criteria: 1) original trials, 2) human trials, 3) intervention and
control groups received of vitamin D and calcium supplementation, and
placebo, respectively and 4) the trials reported mean changes or mean
diﬀerence of body composition and/or metabolic proﬁles with standard
deviation (SD) for the intervention and control groups.
2.2. Data extraction and quality assessment
Two authors (OT, and AD) independently extracted the data and
assessed its quality using standard forms and the Cochrane
Collaboration risk of bias tool [16,17], respectively. This tool is based
on information on the following domains: randomization generation,
allocation concealment, blinding of subjects and outcome assessment,
incomplete outcome data, and selective outcome reporting, and other
sources of bias. When there was disagreement among them, it resolved
by third author (ZA). Eligible studies were abstracted: 1) ﬁrst authors’
name 2) publication year 3) age, sex, and body composition and/or
metabolic proﬁles of study participants and associated measures of
variance 4) study location 5) number of subjects in the intervention and
control groups 6) study design 7) duration of the intervention.
2.3. Data analysis
2.3.1. Heterogeneity and publication biases
The statistical heterogeneity across the results of the included stu-
dies was tested using chi-square test [18], and quantiﬁed by the I2
statistic [19]. Publication bias was assessed by the funnel plot and
tested for statistical signiﬁcance using the Egger's test [20].
2.3.2. Summary measures
We calculated the mean diﬀerence for the inﬂuence of vitamin D
supplementation on EDSS for each included studies. The change score
approach was used to obtain the eﬀect sizes, because the correlations
between baseline and end measurements were more than 1/2 [21]. A
meta-analysis was performed to obtain the summary measures for the
eﬀect of vitamin D administration on EDSS using the inverse variance
method. The random eﬀects model was used to report the pooled mean
diﬀerence with 95% conﬁdence interval (CI). P-values< 0.05 were
considered as statistically signiﬁcant. Because of the low number of
included RCTs and low sample size in the studies, we calculated the
power of this meta-analysis [22]. Statistical analyses were performed
using both Stata version 11.0 (Stata Corp., College Station, TX) and
Review Manager 5.3.
3. Results
3.1. Description of the included RCTs
Our initial search found 11,487 potential citations. After screening,
6 studies were evidenced to be eligible for meta-analysis. Fig. 1 shows
the details of step-by-step study identiﬁcation and selection. The key
characteristics of the RCTs are summarized in Table 1. Trials was
published between 2010 and 2013. These 6 selected studies included
331 randomized participants including 166 and 165 participants in the
intervention and control groups, respectively.
3.2. Eﬀects of vitamin d supplementation on EDSS
The ﬁndings demonstrated that supplementation with vitamin D
alone and vitamin D plus calcium did not aﬀect EDSS (WMD -0.11
(-0.33, 0.11); P= 0.32) (Fig. 2). In addition, sub-group analysis showed
that vitamin D administration alone did not inﬂuence EDSS (WMD
-0.13 (-0.36, 0.11); P= 0.29) and (WMD -0.08 (-0.57, 0.41); P= 0.76),
respectively, compared to placebo, and vitamin D plus calcium sup-
plementation.
3.3. Heterogeneity and publication bias
The results of the chi-square test indicated there was considerable
heterogeneity across the results of the included RCTs. The overall I2 for
studies assessed the impact of vitamin D administration on EDSS was
88% (P < 0.001). We performed the subgroup analysis based on the
comparison groups, the I2 for vitamin D versus placebo and calcium
supplementations were 76% and 94% respectively (Fig. 2). Results of
Fig. 1. Literature search and review ﬂowchart for selection of studies.
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publication bias assessment showed that the included studies in this
meta-analysis scattered nearly symmetrically around the null value in
the funnel plot. So there was no evidence of publication bias (Fig. 3).
Results of power analysis showed that the power of our meta-ana-
lysis was 11%. In order to achieve a power more than 70 percent, we
need to at least 15 RCTs with on average 150 participants in each arm
of the RCTs.
4. Discussion
This meta-analysis is the ﬁrst report of the eﬀect of vitamin D
supplementation on EDSS among people with MS. This meta-analysis
exhibited that consuming vitamin D supplements did not aﬀect EDSS in
patients with MS.
4.1. The eﬀect of vitamin D supplementation on EDSS
Previous longitudinal studies have reported increased EDSS scores
over time [23,24]. The current meta-analysis showed that vitamin D
intake in people with MS did not inﬂuence EDDS. Diﬀerent dosages, co-
supplementation with other micronutrients and durations of vitamin D
treatment. Multiple observational studies have documented an inverse
link between vitamin D concentrations and the risk of MS. In a meta-
analysis study by Duan et al. [25], it was found that people with MS had
lower levels of 25-hydroxyvitamin D compared with healthy subjects.
In another study, Hewer et al. [26] documented that low vitamin D
concentrations in people with MS were very common. There is an ele-
vating interest in a range of functions of vitamin D and low circulating
vitamin D concentrations play a considerable role in the progress of MS
[26,27]. In addition, James et al. [15] performed a meta-analysis on the
impact of vitamin D administration on the risk of MS relapses, no de-
tectable association between vitamin D and risk of MS relapses was
observed. Furthermore, Pozuelo-Moyano et al. [28] performed a sys-
tematic review of vitamin D intake on MS, but the studies included were
low their sample size. In addition, the studies included in the current
meta-analysis, mean EDSS at study baseline in the treatment and con-
trol groups was 1.46–2.61 and 1.23–3.6, respectively. The range of
diﬀerent EDSS may have diﬀerent responses to vitamin D supple-
mentation. However, mean EDSS improvement in studies included our
meta-analysis was not clinically signiﬁcant. We suggest that higher
doses of vitamin D and longer period of intervention might make results
clinically signiﬁcant. Indeed, in previous studies, multiple factors are
described to predict response to therapy [29,30], and these predictors
vary greatly based on the deﬁnition of response used. In a study by Sa
et al. [31], it was documented that sub-optimal treatment response
appeared to be related only to a more severe EDSS score at study
baseline.
In the present meta-analysis, people with MS had received a range
of diﬀerent dosages and formulations of vitamin D. However, the op-
timum dosage of vitamin D intake for people with MS has not been
established, a study done by Pierrot-Deseilligny et al. [31], it was found
a plateau eﬀect of the action of vitamin D on the relapse rate in people
with MS. Nonetheless, Burton et al. [32] exhibited a trend for the im-
pact of vitamin D on relapse rate with high-dose administration (up to
40,000 IU/day). In addition, variations in formulations of vitamin D
used in the diﬀerent trials would result in variations in the results. Stein
et al. [33] demonstrated that high-dose vitamin D2 (6000 IU/day),
compared to low-dose supplementation (1000 IU/day), was not eﬀec-
tive in reducing MRI lesions in patients with MS. While the eﬃcacy of
vitamin D3 supplementation for treatment of MS in adults has been
evaluated in a few small non-controlled trials with variable results
[34,35], two RCTs conducted over 52 weeks [36,37]. The eﬀect of vi-
tamin D supplementation on EDSS remains unclear. 25(OH)D is present
in the central nervous system of MS patients and may be involved in
local immune regulatory systems in progressive MS [38]. Response of
MS patients to vitamin D administration may depend upon the geneticTa
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proﬁle of both vitamin D-related genes [39] and major histocompat-
ibility complex (MHC) class II genotype [40]. In addition, it has been
reported that in patients with MS, increasing 25-hydroxy vitamin D
levels are associated with decreased production of interferon gamma by
CD4+T cells [41]. Bergman et al. [42] demonstrated that long-term
supplementation of vitamin D (more than 6 months) was necessary to
aﬀect the immune system. This may explain the improvement of EDSS
following supplementation with vitamin D.
4.2. Limitations
There are some limitations in our meta-analysis. Firstly, low number
of included studies and consequently low sample size in the studies may
increase the random error and in addition publication bias. As mean
EDSS at baseline in most studies was< 3, we did not perform a distinct
statistical approach. In addition, due to low number of included studies,
we could not perform subgroup analysis based on duration of inter-
vention.
4.3. Conclusions
Overall, this meta-analysis indicated that in patients with MS,
taking vitamin D alone there was no signiﬁcant eﬀect on EDSS.
However, within the RCTs investigating the eﬀect of high-dose vitamin
D administration on EDSS in people with MS that have been published
so far, there are methodological concerns on formulations of vitamin D,
co-supplementation with other micronutrients, diﬀerent dosage of vi-
tamin D used, and duration of the study and sample size. Therefore,
further larger and longer studies addressing these issues should be
considered.
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